Canaccord analyst Richard Close maintained a Buy rating and $19 price target on Evolent Health after news outlets reported that Passport Health Plan said Medicaid rates in Kentucky were finalized this week, implying a blended positive rate increase of 4.7% for PHP. Close tells investors in a research note that the “positive” news removes a recent overhang on Evolent’s stock and gives him greater confidence in the company’s ability to achieve 2019 guidance. He would be an aggressive buyer of the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.